In a nutshell This study aimed to investigate the safety and effectiveness of ublituximab, umbralisib and ibrutinib combination in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). This study concluded that this combination appears safe and effective for these patients. Some background Patients...
Read More
Since the Human Genome Project published the first draft of the human genome in February 2001, there has been a boom in research and new technologies around genetics. The project revealed that humans have around 20,500 genes. Around 3 million base pairs make up these genes. CRISPR is a new technology that has arisen from this groundbreaking Human Genome...
Read More
In a nutshell This study aimed to investigate the significance of minimal residual disease in relation to survival in patients with B-cell acute lymphoblastic leukemia. This study concluded that minimal residual disease may be useful in assessing prognosis and guiding treatment decisions in these patients. Some background Minimal...
Read MoreIn a nutshell This study aimed to compare levels of early complete remission in patients with acute myeloid leukemia (AML) treated with standard or sequential high-dose chemotherapy. This study concluded that sequential high-dose chemotherapy led to early complete remission in these patients. Some background Sequential high-dose...
Read MoreIn a nutshell This study aimed to investigate the long-term safety and effectiveness of inotuzumab ozogamicin (Besponsa) for patients with relapsed or unresponsive acute lymphoblastic leukemia. This study concluded that this treatment was safe and effective for these patients. Some background Inotuzumab ozogamicin (InO) is a targeted...
Read More
In a nutshell This phase 2 trial is evaluating the effectiveness of acalabrutinib (Calquence) with or without obinutuzumab (Gazyva) for chronic lymphocytic leukemia (CLL). The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer. This study is being conducted in Phoenix, Arizona,...
Read MoreIn a nutshell This phase 2 trial is evaluating the effectiveness of huCART19 cell therapy in young patients with high-risk B-cell acute lymphoblastic leukemia (ALL). The main outcome to be measured will be survival without a treatment-related complication. This study is being conducted in Philadelphia, Pennsylvania, United States. The details Acute...
Read More
In a nutshell This study aimed to investigate the rate of deep molecular response in patients with newly diagnosed chronic myeloid leukemia who were treated with nilotinib. This study concluded that good molecular response rates are seen in these patients. Some background Molecular response (MR) is a measure of the levels of BCR-ABL1 gene in leukemia...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of the combination of pracinostat and azacitidine in patients aged over 65 with newly diagnosed acute myeloid leukemia. This study concluded that this combination is a safe and effective for treating this group of patients. Some background Pracinostat is a new drug that...
Read More
In a nutshell This study aimed to investigate the risk of cardiovascular (heart and blood vessel) side effects in patients with chronic myeloid leukemia who were treated with tyrosine kinase inhibitors. This study concluded that these side effects were more frequent in this group of patients. Some background Cardiovascular events (CVE) have been...
Read More
In a nutshell This study aimed to investigate the impact of the graft-versus-lymphoma effect on the outcomes for patients with leukemia/lymphoma who are treated with reduced-intensity conditioning (RIC) with alemtuzumab (Lemtrada) allogeneic hematopoietic stem cell transplant (allo-HSCT). This study concluded that the graft-versus-lymphoma effect...
Read MoreIn a nutshell This study aimed to investigate the impact of graft-versus-leukemia effect on survival in patients with acute lymphoblastic leukemia. This study concluded that graft-versus-leukemia effect was beneficial in certain subsets of these patients. Some background Allogeneic hematopoietic stem cell transplant (allo-HSCT) is a potentially...
Read More
